Clinical Trials on Leukemia, Megakaryoblastic, Acute in China

Total 2021 results

PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)

China
Beijing Boren Hospital

Recruiting

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Beijing Boren Hospital

Active, not recruiting

Study of Sequential CAR-T Cell Treating Leukemia Children

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

Patients With Recurrent Acute Myelogenous Leukemia After Transplantation

China
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Recurrent Adult Acute Myeloid Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Recruiting

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Unknown

Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT

Acute Myeloid Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning

China
The First Affiliated Hospital of Soochow University

Completed

Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

China
Nanfang Hospital of Southern Medical University

Enrolling by invitation

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Acute Myeloid Leukemia | FLT3-ITD Mutation | Brutons Tyrosine Kinase

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

VA vs DA for Newly Diagnosed Hig-risk AML

Acute Myeloid Leukemia

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Completed

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

Acute Myeloid Leukemia | Conditioning | Autologous Hematopoietic Stem Cell Transplantation

China
Shanghai General Hospital, Shanghai Jiao Tong University...
Changhai Hospital; Xiangya Hospital of Central South University; Tongji Hospital and other collaborators

Recruiting

CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML

High Risk Acute Myeloid Leukemia | Allogeneic Hematopoeitic Stem Cell Transplantation

China
Shanghai General Hospital, Shanghai Jiao Tong University...
Changhai Hospital; Xiangya Hospital of Central South University; Tongji Hospital and other collaborators

Recruiting

CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

High Risk Acute Myeloid Leukemia | Allogeneic Hematopoeitic Stem Cell Transplantation

China
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
Shenzhen BinDeBio Ltd.
Children's Hospital of Fudan University

Active, not recruiting

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

T-Cell Acute Lymphoblastic Leukemia

China
Changhai Hospital

Unknown

AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

Acute Myeloid Leukemia | AML1-ETO Fusion Protein Expression

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Ascentage Pharma Group Inc.

Not yet recruiting

A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Nanfang Hospital of Southern Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First People's Hospital... and other collaborators

Completed

Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia | Gene Abnormality | Cytogenetic Abnormality

China
The First Affiliated Hospital of Soochow University

Recruiting

Avapritinib in CBF-AML With KIT Mutations

Core Binding Factor Acute Myeloid Leukemia | KIT Mutation-Related Tumors

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies

Infections | Acute Myeloid Leukemia | Gut Microbiota | Adult

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital of Soochow University

Completed

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Philadelphia Chromosome | Mixed Phenotype Acute Leukemia

China
Shenzhen BinDeBio Ltd.
Xiangya Hospital of Central South University

Recruiting

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia

China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Secondary Acute Myeloid Leukemia Evolving From MDS

China
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

B Acute Lymphoblastic Leukemia | High Risk Acute Lymphoblastic Leukemia | Ph-Negative ALL

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Completed

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Refractory Leukemia | Relapse Leukemia

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditions | Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

AML | Refractory | Relapsed

China
Maxinovel Pty., Ltd.

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Relapsed/Refractory Acute Myeloid Leukemia

China
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaborators

Unknown

Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

Acute Myeloid Leukemia | Thrombocytopenia | Eltrombopag

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Acute Myeloid Leukemia

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Unknown

Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Acute Myeloid Leukemia

China
Peking University People's Hospital

Unknown

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Acute Myeloid Leukemia

China

Clinical Trials on Leukemia, Megakaryoblastic, Acute in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations